Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs

Curr Pharm Des. 2014;20(27):4346-56. doi: 10.2174/1381612819666131118170717.

Abstract

The emergence of multi- and extensively-drug resistant strains of Mycobacterium tuberculosis makes the development of novel anti-tubercular compounds and the identification of alternative mycobacterial drugable targets urgent priorities. Recently, type VII secretion systems (T7SS) have been discovered in mycobacteria. The genome of M. tuberculosis encodes 5 of such systems (ESX-1 to -5), three of which have been characterized and shown to be essential for viability (ESX-3, ESX-5) or virulence (ESX-1, ESX-5). Because of their crucial role in host-pathogen interactions as well as their involvement in basic biological processes of tubercle bacilli, T7SS/ESX represent promising targets for novel anti-tuberculosis drugs. Here, we review the current knowledge of the T7SS/ESX and their impact on M. tuberculosis physiology and virulence. Finally, we discuss the possible approaches to develop T7SS/ESX inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antitubercular Agents* / chemistry
  • Antitubercular Agents* / pharmacology
  • Bacterial Proteins / chemistry
  • Bacterial Proteins / genetics*
  • Bacterial Proteins / metabolism
  • Bacterial Secretion Systems / drug effects*
  • Bacterial Secretion Systems / genetics
  • Base Sequence
  • Binding Sites
  • Cell Wall / metabolism
  • Drug Discovery / methods*
  • Molecular Sequence Data
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / metabolism
  • Mycobacterium tuberculosis / pathogenicity
  • Sequence Alignment
  • Virulence

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • Bacterial Secretion Systems